219 related articles for article (PubMed ID: 22550575)
1. Effects of combined opioids on pain and mood in mammals.
Rech RH; Mokler DJ; Briggs SL
Pain Res Treat; 2012; 2012():145965. PubMed ID: 22550575
[TBL] [Abstract][Full Text] [Related]
2.
Huang P; Ho CK; Cao D; Inan S; Rawls SM; Li M; Huang B; Pagare PP; Townsend EA; Poklis JL; Halquist MS; Banks M; Zhang Y; Liu-Chen LY
J Pharmacol Exp Ther; 2024 Feb; 389(1):106-17. PubMed ID: 38409113
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
[TBL] [Abstract][Full Text] [Related]
4. Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.
Townsend EA
Psychopharmacology (Berl); 2021 Apr; 238(4):1017-1028. PubMed ID: 33404739
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.
Abraham AD; Schattauer SS; Reichard KL; Cohen JH; Fontaine HM; Song AJ; Johnson SD; Land BB; Chavkin C
J Neurosci; 2018 Sep; 38(37):8031-8043. PubMed ID: 30076211
[TBL] [Abstract][Full Text] [Related]
6. Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects.
Santino F; Gentilucci L
Molecules; 2023 Jan; 28(1):. PubMed ID: 36615540
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
8. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.
Minervini V; Dahal S; France CP
J Pharmacol Exp Ther; 2017 Feb; 360(2):280-287. PubMed ID: 27903642
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.
Zhou Y; Freeman K; Setola V; Cao D; Kaski S; Kreek MJ; Liu-Chen LY
Handb Exp Pharmacol; 2022; 271():137-162. PubMed ID: 33834276
[TBL] [Abstract][Full Text] [Related]
10. Effects of butorphanol on morphine-induced itch and analgesia in primates.
Lee H; Naughton NN; Woods JH; Ko MC
Anesthesiology; 2007 Sep; 107(3):478-85. PubMed ID: 17721251
[TBL] [Abstract][Full Text] [Related]
11. Estrogen facilitates and the kappa and mu opioid receptors mediate antinociception produced by intrathecal (-)-pentazocine in female rats.
Robinson DL; Nag S; Mokha SS
Behav Brain Res; 2016 Oct; 312():163-8. PubMed ID: 27312267
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive interactions of micro- and kappa-opioid agonists in the colorectal distension assay in rats.
Briggs SL; Rech RH
Pharmacol Biochem Behav; 2009 Apr; 92(2):343-50. PubMed ID: 19353808
[TBL] [Abstract][Full Text] [Related]
13. Involvement of kappa-opioid receptors in visceral nociception in mice.
Larsson MH; Bayati A; Lindström E; Larsson H
Neurogastroenterol Motil; 2008 Oct; 20(10):1157-64. PubMed ID: 18643891
[TBL] [Abstract][Full Text] [Related]
14. A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.
Edwards KA; Havelin JJ; Mcintosh MI; Ciccone HA; Pangilinan K; Imbert I; Largent-Milnes TM; King T; Vanderah TW; Streicher JM
J Pain; 2018 Jun; 19(6):612-625. PubMed ID: 29371114
[TBL] [Abstract][Full Text] [Related]
15. The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.
Dalefield ML; Scouller B; Bibi R; Kivell BM
Front Pharmacol; 2022; 13():837671. PubMed ID: 35795569
[TBL] [Abstract][Full Text] [Related]
16. Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain.
Distrutti E; Cipriani S; Renga B; Mencarelli A; Migliorati M; Cianetti S; Fiorucci S
Mol Pain; 2010 Jun; 6():36. PubMed ID: 20540729
[TBL] [Abstract][Full Text] [Related]
17. Exposure to morphine-associated cues increases mu opioid receptor mRNA expression in the nucleus accumbens of Wistar Kyoto rats.
Dennis TS; Beck KD; Cominski TP; Bobzean SAM; Kuzhikandathil EV; Servatius RJ; Perrotti LI
Behav Brain Res; 2016 Oct; 313():208-213. PubMed ID: 27421830
[TBL] [Abstract][Full Text] [Related]
18. Does the kappa opioid receptor system contribute to pain aversion?
Cahill CM; Taylor AM; Cook C; Ong E; Morón JA; Evans CJ
Front Pharmacol; 2014; 5():253. PubMed ID: 25452729
[TBL] [Abstract][Full Text] [Related]
19. Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.
Sadee W; Oberdick J; Wang Z
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932935
[TBL] [Abstract][Full Text] [Related]
20. Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal κ- and μ-opioid receptor heterodimerization and female-specific spinal morphine antinociception.
Liu NJ; Chakrabarti S; Schnell S; Wessendorf M; Gintzler AR
J Neurosci; 2011 Aug; 31(33):11836-45. PubMed ID: 21849544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
